Raymond Yang
About Raymond Yang
Raymond Yang is an Associate Scientist currently employed at Mammoth Biosciences in Brisbane, California. He has a diverse background in biological sciences, having held various positions at organizations such as Codiak BioSciences, Beam Therapeutics, and Biogen Idec.
Current Role at Mammoth Biosciences
Raymond Yang serves as an Associate Scientist at Mammoth Biosciences, a position he has held since 2022. He works in Brisbane, California, contributing to the company's efforts in developing innovative CRISPR-based diagnostics and therapeutics. His role involves applying his scientific expertise to advance the company's research initiatives.
Previous Experience at Beam Therapeutics
Prior to his current role, Raymond Yang worked at Beam Therapeutics as a Senior Research Associate in Non-Viral Delivery from 2019 to 2022. During his three years at the company, he focused on developing non-viral delivery methods for gene editing technologies, contributing to the advancement of therapeutic applications.
Experience at Codiak BioSciences
Raymond Yang had two significant roles at Codiak BioSciences. He first served as a Research Associate from 2016 to 2018, where he was involved in research projects related to exosome-based therapeutics. He later advanced to the position of Senior Associate Scientist in 2019, where he continued to contribute to the company's scientific objectives for nearly a year.
Educational Background in Biology
Raymond Yang earned a Bachelor of Science (B.S.) degree in Biology/Biological Sciences from Northeastern University. His educational background provided a solid foundation for his career in the life sciences, equipping him with the necessary knowledge and skills for his various roles in research and development.
Early Career and Internships
Raymond Yang began his career with several internships and co-op positions that shaped his professional development. He worked as an Immunology Intern at Tufts University School of Medicine in 2014, and held co-op positions at Biogen Idec and Shire in 2014 and 2015, respectively. These early experiences contributed to his understanding of drug discovery and therapeutic development.